推 cooltyus:... 09/25 22:17
維基解密網站: http://wikileaks.org/
一堆人在看政治議題
我好奇用google查了一下
關鍵字: "taiwan" Pharmaceutical price site:wikileaks.org
文章還真不少
隨便瀏覽其中一篇
他們連global budget都在討論.......
http://wikileaks.org/cable/2005/01/05TAIPEI17.html
?19. Medical Devices: Registration and approval procedures
for medical device imports are complex and time-consuming,
and have been the subject of long-standing complaints by
U.S. firms. The registration process requires redundant
testing, and foreign manufacturers must re-register new
products even though they are based on previously approved
devices. In addition, it is unclear when local clinical
trials are required for the review process or whether
industry is allowed to provide additional input in response
to questions posed by DOH officials reviewing the clinical
trial submissions. The adoption of the U.S. Food and Drug
Administration's medical device classification system in
June 2000 was welcomed by industry. However, Taiwan's
implementation of this system in 2004 was faulted by
industry for requiring re-registration of previously
approved products. Taiwan has identified both the medical
device and pharmaceutical sectors as priorities for local
development, resulting in Taiwan's agencies often favoring
the interests of local companies over foreign firms.
?20. Pharmaceuticals: Taiwan's lengthy pharmaceutical
registration process slows market entry for new drugs that
have already been approved in other economies and also
imposes unnecessary costs on drugs that have been approved
in Taiwan. In May 2001, the DOH announced a requirement for
firms to submit voluminous amounts of proprietary
manufacturing data as part of the registration and approval
process for both new drugs and those already on the market.
The amount of such "validation" data requested by Taiwan far
exceeded international norms. In response to concerns
raised by the United States and its industry, the DOH had
postponed implementation of this requirement. In December
2002, the United States and Taiwan exchanged letters in
which Taiwan affirmed its commitment to adhere to
international practices as applied in advanced economies,
and agreed that firms can demonstrate validation status by
providing documentary evidence, including abridged
registration applications. In August 2003, DOH and the U.S.
industry reached agreement on validation data resolutions.
However, DOH has announced plans to assign risk based
"priority numbers" that will be used to determine which
manufacturers are inspected by DOH. US industry is
concerned that these risk priority numbers are based on non-
transparent criteria and inspections will unfairly target
manufacturers that provide abridged data. Discussions
between the United States and Taiwan to resolve remaining
issues are ongoing.
?21. Taiwan uses various methods to lower assigned prices on
innovative drugs, including "reference pricing" (assigning a
lower price when a drug is approved for an additional use)
and lowering assigned prices without a transparent process.
In addition, Taiwan continues to restrict consumer choice
and limit U.S. market access through disproportionate
reimbursement of domestically manufactured generic drugs.
To address these outstanding concerns of foreign
pharmaceutical firms, Taiwan announced a reimbursement-
pricing plan in March 2003. In this plan, the DOH and the
Bureau of National Health Insurance agreed to find ways to
include a "reward for innovation" component in its pricing
mechanism for new drugs. However, industry representatives
have criticized the new drug pricing mechanism as non-
transparent and believe the reimbursement prices will not
achieve the stated objective. Discussions between the
United States and Taiwan on this issue are ongoing.
?22. In July 2002, Taiwan introduced a "global budget"
system in which hospitals receive lump sums from the
National Health Insurance system to cover the cost of
providing all services. The goal is to increase efficiency
and encourage cost-cutting measures, but critics contend
that the global budget system primarily encourages hospitals
to seek discounts on pharmaceuticals in order to make up for
losses in providing medical services. In addition, critics
say the system discourages use of innovative drugs.
還有這篇
http://wikileaks.org/cable/2008/04/08TAIPEI572.html
Defensive Moves to Drop Drugs from Market
-----------------------------------------
?16. (SBU) Foreign drug companies in Taiwan also express concern that
countries in the region are starting to reference BNHI's
reimbursement prices when setting drug-reimbursement prices in their
own healthcare systems. According to several companies'
representatives, in 2007, Korea started to set Taiwan reimbursement
prices as target prices for original-drug manufacturers' products in
Korea. Wyeth's Wang said that China and Thailand were also starting
to reference Taiwan's prices--which are both attractively low and
also clearly posted on the BNHI website--when determining their own
domestic drug prices. Wang warned that if this continues, Wyeth
would consider removing drugs from the Taiwan market--even
profitable ones--as a defensive measure to avoid losing money in
other markets. JC's Park said that the company has already pulled
products out of Taiwan for this reason, and echoed Wyeth's concerns
about other countries using Taiwan's reimbursement prices to set
prices in their own markets.
賺錢的藥也下市,只為了怕在其他市場沒得賺那麼多錢,這有沒有藥德?
文章很多,有興趣的一起去看看有沒有和醫藥相關的八卦
--
※ 發信站: 批踢踢實業坊(ptt.cc)
◆ From: 123.192.176.57
※ 編輯: hahawow 來自: 123.192.176.57 (09/25 22:15)